UNC Lineberger Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, UNC Lineberger Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count).
UNC Lineberger Comprehensive Cancer Center: 366 sponsored US clinical trials, 79 recruiting.
UNC Lineberger Comprehensive Cancer Center sponsors 366 registered US clinical trials on ClinicalTrials.gov, 79 of them currently recruiting, and 209 completed. 2 of these trials are in Phase 3-4 (later-stage) and 157 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 29 trials.
Top-decile sponsor footprint
UNC Lineberger Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
209 of 246 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
366 total, page 2 of 8
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
NCT06096623
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05542407
Brain Slice Explants to Predict Drug Response in Brain Tumors
NCT05978557
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
NCT05620342
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
NCT05743426
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
NCT05754749
Young Adult Infusion Space Experience Satisfaction Survey
NCT05720546
Evaluation of Child Care Staff Weight Management Program
NCT05656807
Adaptation of a Values Assessment Tool
NCT07068477
Study of Trilaciclib and Lurbinectidin
NCT05578326
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
NCT05366179
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
NCT05440929
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
NCT05472792
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
NCT05145400
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
NCT05096923
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
NCT04564989
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
NCT04223765
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT04099290
MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
NCT04073966
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
NCT04083495
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT03977233
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
NCT03721068
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT03769415
Registry for Adults With Plasma Cell Disorders (PCD's)
NCT03717844
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT03454035
UNC Pleural Fluid Registry
NCT05620329
Registry of Older Patients With Cancer
NCT01137825
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
NCT01137643
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
NCT01000883
Physical Activity Centers Empowerment
NCT06411756
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
NCT05911321
Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers
NCT05823740
Impact of Financial Incentives
NCT05744960
Impact of Standing Orders Optimization
NCT05742386
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05498220
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
NCT05926024
Pembrolizumab Plus Olaparib in LA-HNSCC
NCT05366166
Patient Related Outcomes for Gynecologic Radiation Oncology
NCT04753086
PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology
NCT05592665
Immuno-Oncology Database and Bioregistry
NCT04656873
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
NCT04670068
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
NCT04548648
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
NCT03978624
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
NCT03529422
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
NCT04134325
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
NCT03696784
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
NCT03672318
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
NCT03602157
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
NCT03264131
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
NCT03174275
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 71 |
| Phase 2 | 86 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the UNC Lineberger Comprehensive Cancer Center pipeline
79 recruiting of 366 indexed (22% open); 209 completed (57%).
Phase mix: 2 late (III/IV) vs 157 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
UNC Lineberger Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 366 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 366 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Women and Infants Hospital of Rhode Island · 22% recruiting · 65 trials
- Merck Sharp & Dohme · 22% recruiting · 558 trials
- Henry M. Jackson Foundation for the Advancement of Military Medicine · 22% recruiting · 60 trials
- AbbVie · 21% recruiting · 526 trials
Related
What to do with this UNC Lineberger Comprehensive Cancer Center page
366 registered trials is a research-attention snapshot, not an endorsement of UNC Lineberger Comprehensive Cancer Center or any single study.
- 79 of UNC Lineberger Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition UNC Lineberger Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
UNC Lineberger Comprehensive Cancer Center pipeline card: 366 registered trials from official public datasets.Report a data error.